Switzerland· 66792001

Cablivi

A caplacizumab product containing caplacizumabum, registered in Switzerland and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC B01AX07

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedCabliviATCB01AX07REGISTER NO.66792001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Caplacizumab is registered in 12 of 19 countries.

Countries holding a registration under ATC B01AX07 (caplacizumab), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Caplacizumab · ATC B01AX07

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of caplacizumab costs, country by country.

Normalised to the WHO defined daily dose (10 mg), so markets compare like for like.

  • Switzerland: $4847.79 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Caplacizumab · price per daily dose (10 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$4847.79
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
caplacizumabum
Manufacturer
—
Country
Switzerland (CH)
ATC code
B01AX07
ATC class
Caplacizumab
Defined daily dose
10 mg, P
Swissmedic category
B
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680667920014
    Durchstf 1 Stk
    CHF 4020.4

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

142 interactions on record for caplacizumab.

Graded by severity as the source publishes them — 72 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Caplacizumab · interactions on record

142 records

  • 72 severe
  • 70 moderate

Most severe, free to view

  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • HeparinB01AB01severe
  • Antithrombin IIIB01AB02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Caplacizumab in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All caplacizumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Cablivi
  • Liechtenstein · Cablivi
  • Norway · Cablivi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/8985e726-f001-4435-bd4e-02ff7b052f63
GET /v1/drugs/8985e726-f001-4435-bd4e-02ff7b052f63?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "caplacizumabum 10 mg",
  "valid_from": "2025-01-01",
  "limitations": "[{\"description\":\"Cablivi wird vergütet zur Behandlung von Erwachsenen und Jugendlichen im Alter von 12 Jahren und älter mit einem Körpergewicht von mindestens 40 kg, die an einer Episode von erworbener thrombotisch-thrombozytopenischer Purpura (acquired thrombotic thrombocytopenic purpura, aTTP) leiden, in Verbindung mit Plasmapherese und Immunsuppression.<br>\\n<br>\\nDie Behandlung mit CABLIVI hat bis zu einem ADAMTS13 Aktivitäts-Schwellenwert von mindestens 20% mit einem bestätigten Aufwärtstrend (bestimmt anhand von 2 Messungen aus dem gleichen Labor) zu erfolgen. Anschliessend erfolgt keine Vergütung mehr.<br>\\n<br>\\nDie Sanofi-Aventis (Schweiz) AG erstattet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin für jede bezogene Packung CABLIVI einen festgelegten Anteil des Fabrikabgabepreises zurück. Sie gibt dem Krankenversicherer die Höhe der Rückerstattung bekannt.<br>\\n <br>\\nErfolgt die Therapie bis zu einem ADAMTS13 Aktivitäts-Schwellenwert von mindestens 20% und nach Absetzen der Therapie tritt innerhalb eines Monates ein Rezidiv auf, erstattet Sanofi-Aventis (Schweiz) AG erstattet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin für jede bezogene Packung CABLIVI einen festgelegten höheren Anteil des Fabrikabgabepreises zurück. Sie gibt dem Krankenversicherer auch die Höhe dieser Rückerstattung bekannt.<br>\\n<br>\\nDie Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden. Die Aufforderung zur Rückerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen. Folgender Code ist an den Krankenversicherer zu übermitteln: 20955.01<br>\\n<br>\",\"costApproval\":null,\"indication\":\"20955.01\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2025-01-01\",\"validTo\":\"2027-12-31\"}]",
  "galenic_form": "Trockensub 10 mg c Solv",
  "therapeutic_area": null,
  "sl_inclusion_date": "2025-01-01",
  "self_retention_pct": 10
}

See everything about caplacizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.